ProRelix Research proudly announces the successful enrollment of the first patient in a Phase 1/2 clinical trial for locally advanced cervical cancer at Siriraj Hospital, Thailand. This milestone marks significant progress in global oncology clinical research and supports the development of innovative treatment approaches aimed at improving patient outcomes. The study is planned for expansion across Asia and the United States, reflecting ProRelix Research’s continued commitment to advancing high-quality clinical research, supporting impactful global oncology trials, and advancing innovative oncology therapies.
ProRelix Research proudly received the NextGen Pharma Awards 2026 on 24th April 2026 in Hyderabad, under the category of Excellence in Clinical Research Services. The award was received by our Director, Mr. Niranjan Andhalkar, from Shri Damodar Raja Narasimha, Minister for Health, Medical & Family Welfare, Government of Telangana, recognizing our continued commitment to delivering high-quality clinical research solutions and contributing to advancements in the healthcare and pharmaceutical industry.
ProRelix Research proudly received the MSME National Golden Business Excellence Award on 23rd March 2026 in New Delhi, under the category of Excellence in Quality CRO Business in Healthcare at the MSMECCII 2nd National Business Excellence Award 2026. The award was received by our Director, Mr. Niranjan Andhalkar, recognizing our excellence and commitment to quality in the clinical research industry.
ProRelix Research is pleased to announce its participation in PharmaCore India 2026, a key platform for pharmaceutical and clinical research advancements. This event presents an excellent opportunity for us to connect with industry leaders, innovators, and stakeholders contributing to the future of drug development, healthcare innovation and excellence in clinical research, pharmacovigilance, and regulatory solutions.
ProRelix Research is pleased to announce its participation in Vitafoods India 2026, one of India’s leading nutraceutical and functional ingredients exhibitions. This event represents an important opportunity for us to engage with industry leaders, innovators, and stakeholders shaping the future of nutrition, health, and clinical research.
While scientific breakthroughs capture headlines, the defining challenge of modern healthcare lies in bridging the gap between pioneering discovery and consistent, real-world patient outcomes. Guiding this critical translation with a blend of strategic foresight and operational pragmatism is Niranjan Andhalkar, Director – Strategic Management & Planning at ProRelix Research.
ProRelix Research is proud to announce its participation in CPHI & PMEC India 2025, the country’s largest pharmaceutical networking event. This marks a significant step in our mission to deepen global collaboration and accelerate development in clinical research.
ProRelix Research has broadened its clinical trial footprint across Europe and Southeast Asia, reinforcing its global reach and advancing its capability to conduct patient-centric, regulatory-compliant studies with excellence.
ProRelix Research has expanded its clinical trial operations into multiple countries across Europe and Southeast Asia, enhancing its ability to deliver patient-focused, fully compliant global studies.
ProRelix Research has expanded its clinical trial operations into multiple countries across Europe and Southeast Asia, enhancing its ability to deliver patient-focused, fully compliant global studies.
ProRelix Research is heading to Vitafoods Asia 2025 in Bangkok, showcasing our expertise in clinical research, regulatory support, and innovative life sciences solutions while connecting with industry leaders.
ProRelix Research ensures faster start-up, fewer cost overruns, and stronger sponsor trust through protocol-driven, transparent clinical trial budgeting and streamlined scope management.
Decentralized clinical trials are reshaping research with greater efficiency, accessibility, and patient engagement. ProRelix Research leads this evolution through technology-driven, patient-centric solutions.
ProRelix Services LLP is now officially registered with CDSCO, strengthening our commitment to regulatory excellence and enabling high-quality, compliant global trials across the US, EU, and APAC.
ProRelix Research will join CPHI & PMEC China 2025 from 24–26 June at SNIEC, Shanghai, showcasing our global expertise in Clinical Research, Data Management, Medical Writing, Pharmacovigilance, Regulatory Affairs, and ICH GCP Compliance.
ProRelix Research will be at Pharma Live Expo & Summit 2025, Mumbai, on 18th April—showcasing our expertise in clinical research, regulatory affairs, and global partnerships to drive healthcare innovation.
ProRelix Research will participate in BioAsia 2025 on 25–26 February at HICC, Hyderabad. Join us at Asia’s premier life sciences event to explore partnerships and innovations in clinical development.
ProRelix Research will participate in HPCI India 2025 on 18–19 Feb at Jio World Convention Centre, Mumbai, showcasing expertise in Clinical Research, Data Management, and Medical Writing. Visit us to explore innovative solutions and collaborate for industry growth.
ProRelix Research will be at WHX Labs Dubai Middle East 2025 (Feb 3–6, Dubai World Trade Centre) showcasing expertise in Clinical Research, Regulatory Affairs, Data Management, and healthcare innovations.
ProRelix Research, led by Niranjan Andhalkar, shares cost-optimization strategies for multi-country clinical trials, helping sponsors cut costs while maintaining global efficiency.
ProRelix Research is delighted to join CPHI Middle East 2024 from 10–12 December at Riyadh Front Exhibition & Conference Center, showcasing our clinical research and healthcare expertise to a global audience.
ProRelix Research participated in the 17th ISCR Annual Conference 2024 in Hyderabad, fostering innovation and collaboration to advance clinical research and improve patient outcomes.
ProRelix Research will be at the DIA Annual Meeting 2023, Boston (June 26–28). Meet us at Booth 929 to explore innovative solutions for your global clinical trial needs.
ProRelix Research, an established global CRO based in the USA and India since 2014, has officially launched a dedicated clinical operations office in the United States.
ProRelix Research was honored to be interviewed at the prestigious Health 2.0 Conference, World Trade Center, Dubai, in 2022.
ProRelix Research is pleased to announce its participation in PharmaCore India 2026, a key platform for pharmaceutical and clinical research advancements. This event presents an excellent opportunity for us to connect with industry leaders, innovators, and stakeholders contributing to the future of drug development, healthcare innovation and excellence in clinical research, pharmacovigilance, and regulatory solutions.
ProRelix Research is pleased to announce its participation in Vitafoods India 2026, one of India’s leading nutraceutical and functional ingredients exhibitions. This event represents an important opportunity for us to engage with industry leaders, innovators, and stakeholders shaping the future of nutrition, health, and clinical research.
ProRelix Research is proud to announce its participation in CPHI & PMEC India 2025, the country’s largest pharmaceutical networking event. This marks a significant step in our mission to deepen global collaboration and accelerate development in clinical research.
ProRelix Research is heading to Vitafoods Asia 2025 in Bangkok, showcasing our expertise in clinical research, regulatory support, and innovative life sciences solutions while connecting with industry leaders.
ProRelix Services LLP is now officially registered with CDSCO, strengthening our commitment to regulatory excellence and enabling high-quality, compliant global trials across the US, EU, and APAC.
ProRelix Research will join CPHI & PMEC China 2025 from 24–26 June at SNIEC, Shanghai, showcasing our global expertise in Clinical Research, Data Management, Medical Writing, Pharmacovigilance, Regulatory Affairs, and ICH GCP Compliance.
ProRelix Research will be at Pharma Live Expo & Summit 2025, Mumbai, on 18th April—showcasing our expertise in clinical research, regulatory affairs, and global partnerships to drive healthcare innovation.
ProRelix Research will participate in BioAsia 2025 on 25–26 February at HICC, Hyderabad. Join us at Asia’s premier life sciences event to explore partnerships and innovations in clinical development.
ProRelix Research will participate in HPCI India 2025 on 18–19 Feb at Jio World Convention Centre, Mumbai, showcasing expertise in Clinical Research, Data Management, and Medical Writing. Visit us to explore innovative solutions and collaborate for industry growth.
ProRelix Research joined Vitafoods India 2025, Mumbai, sharing expertise in Clinical Research, Regulatory Affairs, and Pharmacovigilance while connecting with industry leaders.
ProRelix Research will be at WHX Labs Dubai Middle East 2025 (Feb 3–6, Dubai World Trade Centre) showcasing expertise in Clinical Research, Regulatory Affairs, Data Management, and healthcare innovations.
ProRelix Research is delighted to join CPHI Middle East 2024 from 10–12 December at Riyadh Front Exhibition & Conference Center, showcasing our clinical research and healthcare expertise to a global audience.
ProRelix Research participated in the 17th ISCR Annual Conference 2024 in Hyderabad, fostering innovation and collaboration to advance clinical research and improve patient outcomes.
ProRelix Research will be at the DIA Annual Meeting 2023, Boston (June 26–28). Meet us at Booth 929 to explore innovative solutions for your global clinical trial needs.
ProRelix Research proudly announces the successful enrollment of the first patient in a Phase 1/2 clinical trial for locally advanced cervical cancer at Siriraj Hospital, Thailand. This milestone marks significant progress in global oncology clinical research and supports the development of innovative treatment approaches aimed at improving patient outcomes. The study is planned for expansion across Asia and the United States, reflecting ProRelix Research’s continued commitment to advancing high-quality clinical research, supporting impactful global oncology trials, and advancing innovative oncology therapies.
ProRelix Research proudly received the NextGen Pharma Awards 2026 on 24th April 2026 in Hyderabad, under the category of Excellence in Clinical Research Services. The award was received by our Director, Mr. Niranjan Andhalkar, from Shri Damodar Raja Narasimha, Minister for Health, Medical & Family Welfare, Government of Telangana, recognizing our continued commitment to delivering high-quality clinical research solutions and contributing to advancements in the healthcare and pharmaceutical industry.
ProRelix Research proudly received the MSME National Golden Business Excellence Award on 23rd March 2026 in New Delhi, under the category of Excellence in Quality CRO Business in Healthcare at the MSMECCII 2nd National Business Excellence Award 2026. The award was received by our Director, Mr. Niranjan Andhalkar, recognizing our excellence and commitment to quality in the clinical research industry.
While scientific breakthroughs capture headlines, the defining challenge of modern healthcare lies in bridging the gap between pioneering discovery and consistent, real-world patient outcomes. Guiding this critical translation with a blend of strategic foresight and operational pragmatism is Niranjan Andhalkar, Director – Strategic Management & Planning at ProRelix Research.
ProRelix Research has broadened its clinical trial footprint across Europe and Southeast Asia, reinforcing its global reach and advancing its capability to conduct patient-centric, regulatory-compliant studies with excellence.
ProRelix Research has expanded its clinical trial operations into multiple countries across Europe and Southeast Asia, enhancing its ability to deliver patient-focused, fully compliant global studies.
ProRelix Research explores how investigator-initiated trials are now driving clinical innovation, bridging investigator ambition, regulatory rigor, and CRO expertise to turn ideas into impactful research
ProRelix Research ensures faster start-up, fewer cost overruns, and stronger sponsor trust through protocol-driven, transparent clinical trial budgeting and streamlined scope management.
Decentralized clinical trials are reshaping research with greater efficiency, accessibility, and patient engagement. ProRelix Research leads this evolution through technology-driven, patient-centric solutions.
ProRelix Research, led by Niranjan Andhalkar, shares cost-optimization strategies for multi-country clinical trials, helping sponsors cut costs while maintaining global efficiency.
ProRelix Research, an established global CRO based in the USA and India since 2014, has officially launched a dedicated clinical operations office in the United States.
ProRelix Research was honored to be interviewed at the prestigious Health 2.0 Conference, World Trade Center, Dubai, in 2022.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.
